Portal de Periódicos da CAPES

Antihypertensive activity of verapamil: impact of dietary sodium

1993; Lippincott Williams & Wilkins; Volume: 11; Issue: 6 Linguagem: Inglês

10.1097/00004872-199306000-00011

1473-5598

J. Redon-Mas, J. Abellan-Alemán, Pedro Aranda-Lara, Mariano de la Figuera-Von Wichmann, Manuel Luque-Otero, Jose Luis Rodicio-Dïaz, Luis M. Ruilope-Urioste, Javier Velasco-Quintana,

Sodium Intake and Health

Objective: To define the influence of dietary salt intake on the antihypertensive effect of slow-release verapamil 240 mg once a day in a population with mild-to-moderate essential hypertension. Design: Parallel, randomized, multicentre study. Methods: Patients were advised to follow a moderately low salt diet (Low—salt group). After a 2—week run—in period, those patients with 24—h urinary sodium excretion (UNa) ≤120mmol/day and a diastolic blood pressure (DBP) between 90 and 114mmHg were randomly assigned to verapamil + Low—salt or verapamil + unrestricted—salt diet (High—salt group) for 28 days. Compliance with diets was defined as Low—salt UNa ≤120mmol/day and High—salt UNa120mmol/day with UNa increased by ≥60mmol/day over the level attained at the end of the run-in period. Results: Significant reductions in mean systolic blood pressure ( SBP) and DBP were found in both the Low—salt (n=235) and High—salt (n=183) groups. The therapeutic goal (DBP<90mmHg) was achieved in 38.3% of patients in the Low—salt and 44.8% of patients in the High—salt group. Office blood pressure results were confirmed by ambulatory 24—h blood pressure monitoring in a subsample of patients. Verapamil reduced mean blood pressure throughout the nycthemeral cycle without any significant difference between the two groups. Conclusion: The restriction in sodium intake does not have an additive effect on the antihypertensive effect of the slow—channel calcium antagonist verapamil.